首页> 外文期刊>Arthritis Research >Therapeutic impact of the ethyl acetate extract of Tripterygium wilfordii Hook F on nephritis in NZB/W F1 mice
【24h】

Therapeutic impact of the ethyl acetate extract of Tripterygium wilfordii Hook F on nephritis in NZB/W F1 mice

机译:雷公藤乙酸乙酯提取物乙酸乙酯提取物对NZB / W F1小鼠肾炎的治疗作用

获取原文
           

摘要

This study was designed to examine the potential use of the ethyl acetate (EA) extract of Tripterygium wilfordii Hook F (TwHF), a Chinese herbal medicine, in the treatment of systemic lupus erythematosus. A total of 48 28-week-old female NZB/W F1 mice were randomly divided into three groups and orally administered vehicle or the EA extract of TwHF at 18.25 mg/kg (EAlow) or 36.5 mg/kg (EAhigh) for 14 weeks. Proteinuria and serum anti-double-stranded (ds)DNA antibody titers were assayed before and after treatment. At the end of treatment, all animals were sacrificed and pathological changes in the kidneys were examined by observers blinded to the treatment regimens. Immunohistological studies were carried out on kidneys and spleens. At 28 weeks of age, proteinuria (>30 mg/dl) and anti-dsDNA antibodies were found in all mice in the three groups. Fourteen, sixteen and fifteen mice in the vehicle, EAlow and EAhigh groups, respectively, completed at least four weeks of treatment. At the end of treatment, the mean proteinuria of the EAlow and EAhigh groups was significantly less than that of the vehicle group and no different from proteinuria at the onset of treatment. Histological evidence of glomerulonephritis, glomerular deposition of IgG and complement 3 and cellular infiltration in the interstitium and perivascular regions were significantly less severe in the EA extract treated mice than in vehicle treated mice. Treatment with the EA extract significantly inhibited the progression of kidney disease in NZB/W F1 mice, though had no significant effect on the levels of anti-dsDNA antibody.
机译:这项研究的目的是研究中草药雷公藤的F(TwHF)乙酸乙酯(EA)提取物在系统性红斑狼疮治疗中的潜在用途。将总共​​48只28周龄的NZB / W F1雌性小鼠随机分为三组,口服给予载体或TwHF EA提取物,剂量为18.25 mg / kg(EA low )或36.5 mg / kg(EA high )14周。在治疗前后测定蛋白尿和血清抗双链(ds)DNA抗体滴度。在治疗结束时,处死所有动物并由对治疗方案不知情的观察者检查肾脏的病理变化。对肾脏和脾脏进行了免疫组织学研究。在28周龄时,三组中的所有小鼠均发现蛋白尿(> 30 mg / dl)和抗dsDNA抗体。载体中分别为EA low 和EA high 组的14、16和15只小鼠完成了至少四个星期的治疗。在治疗结束时,EA low 和EA high 组的平均蛋白尿显着低于赋形剂组,并且与治疗开始时的蛋白尿无差异。 EA提取物治疗的小鼠的肾小球肾炎,IgG和补体3的肾小球沉积以及间质和血管周围区域的细胞浸润的组织学证据比媒介物治疗的小鼠严重。用EA提取物处理可显着抑制NZB / W F1小鼠的肾脏疾病进展,尽管对抗dsDNA抗体的水平无明显影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号